menu search

ARAY / Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say

Accuray (ARAY) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Accuray (ARAY) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Read More
Posted: Aug 9 2023, 21:58
Author Name: Zacks Investment Research
Views: 111634

ARAY News  

With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray

By Seeking Alpha
October 6, 2023

With Chinese Type B Approval In Hand, 'Now Or Never' Approaches For Accuray

Accuray's China JV recently received approval to sell its locally-produced Tomo C rad-onc system for China's Type B market - an opportunity that manag more_horizontal

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

By Zacks Investment Research
October 5, 2023

Accuray's (ARAY) Tomo C Radiation System Gets Approval in China

Accuray's (ARAY) Tomo C radiation therapy system will enable medical care teams to provide personalized and highly precise treatments. more_horizontal

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

By Zacks Investment Research
October 3, 2023

Accuray's (ARAY) New Offering to Boost Radiation Treatment Plans

Accuray's (ARAY) latest offering is likely to improve radiation treatment. more_horizontal

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

By Zacks Investment Research
September 8, 2023

Why Is Accuray (ARAY) Down 15.2% Since Last Earnings Report?

Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? more_horizontal

Accuray Incorporated - Impressive Growth As Orders Expands

By Seeking Alpha
August 19, 2023

Accuray Incorporated - Impressive Growth As Orders Expands

Accuray Incorporated has shown impressive growth in its share price and revenues, making it an attractive investment opportunity in the healthcare equ more_horizontal

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

By Zacks Investment Research
August 15, 2023

Accuray's (ARAY) Treatment Options to be Boosted Post FDA's Nod

Accuray's (ARAY) latest regulatory approval is likely to improve breast cancer treatment. more_horizontal

New Strong Sell Stocks for August 11th

By Zacks Investment Research
August 11, 2023

New Strong Sell Stocks for August 11th

NGLOY, ARAY and BANR have been added to the Zacks Rank #5 (Strong Sell) List on August 11, 2023. more_horizontal

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

By Zacks Investment Research
August 10, 2023

Accuray (ARAY) Q4 Earnings and Revenues Lag Estimates

Accuray (ARAY) reports a solid fiscal fourth quarter top line on the back of robust segmental performances. more_horizontal


Search within

Pages Search Results: